Special Issues

Special Issue Title: Targeting the tumor microenvironment for cancer treatment

· Print Special Issue Flyer

· Deadline for manuscript submissions: 31 December 2021


Special Issue Editor

Guest Editor

Cristina P. R. Xavier, PhD

i3S - Institute of Health Research and Innovation, University of Porto, Portugal

Website | E-Mail

Interests: Cancer drug resistance; Extracellular Vesicles (EVs) as mediators of cancer drug resistance; Anticancer activity of compounds (of natural or chemical origin); Impact of the tumor microenvironment on cancer drug resistance; Molecular mechanisms for overcoming drug resistance


Special Issue Information

Dear Colleagues,

Several evidences have shown that the tumor microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Indeed, the TME has been recognized as a major contributor to cancer malignancy and therapeutic resistance. The TME comprises the surrounding blood vessels, signaling molecules, the extracellular matrix (ECM) and multiple stromal cells, including cancer-associated fibroblast (CAFs), tumor-associated macrophages (TAMs), among others. The presence of these cellular components has been associated with poor prognosis and unfavorable outcomes in different types of cancers. Therefore, therapies that simultaneously target tumor cells and TME components may represent a key strategy to overcome drug resistance and improve patient outcomes. This Special Issue includes original research articles focusing on novel bioactive compounds or small molecules (chemically synthesized or of natural origin), or repurposed drugs, that target TME elements to improve cancer therapy. Review articles will also be considered. 

 

Dr. Cristina P. R. Xavier

Guest Editor



Manuscript Submission Information

Manuscripts should be submitted online at https://jmcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Molecular and Clinical Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $500. We normally offer a discount greater than 30%  for high-quality papers. Submitted papers should be well formatted and use good English.


Keywords
Anticancer compounds; Cancer therapy; Repurposed drugs; Small molecules; Therapeutic resistance; Tumor microenvironment


Share This Special Issue

     



Please wait a minute...
For Selected: Toggle Thumbnails

Current Issue

  • Volume 4, Issue 2